Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

PHASE2CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

July 31, 2015

Conditions
Chronic Hepatitis C
Interventions
DRUG

BMS-650032

DRUG

BMS-790052

DRUG

BMS-791325

DRUG

Ribavirin

Trial Locations (32)

9410

Local Institution, Créteil

10468

James J Peters Vamc, The Bronx

13285

Local Institution, Marseille

20007

Medstar Georgetown University Hospital, Washington D.C.

21093

Johns Hopkins University, Lutherville

21202

Mercy Medical Center, Inc., Baltimore

22031

Metropolitan Research, Fairfax

22042

Inova Fairfax Hospital, Falls Church

30308

Atlanta Gastroenterology Associates, Llc, Atlanta

32803

Orlando Immunology Center, Orlando

33143

Miami Research Associates, South Miami

35294

The Kirklin Clinic, Birmingham

53715

Dean Clinic, Madison

74104

Options Health Research, Llc, Tulsa

74135

Healthcare Research Consultants, Tulsa

75679

Local Institution, Paris

76012

Texas Clinical Research Institute, Arlington

77030

Research Specialists Of Texas, Houston

78215

Alamo Medical Research, San Antonio

80045

University Of Colorado Denver And Hospital, Aurora

84106

Lifetree Clinical Research, Salt Lake City

87042

Local Institution, Limoges

87505

Southwest Care Center, Santa Fe

90036

Peter J Ruane Md Inc, Los Angeles

90073

Va Greater Los Angeles Healthcare System, Los Angeles

92105

Research And Education, Inc., San Diego

92114

Precision Research Institute, Llc, San Diego

92118

Southern California Research Center, Coronado

Local Institution, Clichy

92123

Medical Associates Research Group, San Diego

08844

Id Care, Hillsborough

00927

Fundacion De Investigacion De Diego, San Juan

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY